

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jérôme Asius et al.

Serial No.: 09/242,103

Filed: February 8, 1999

For: IMPLANT FOR
SUBCUTANEOUS OR
INTRADERMAL INJECTION

:
:
:
:
:
:
:
:
:
:

Art Unit: 3738

Examiner: C. Koh

Atty Docket: 20198/0047

SUBMISSION OF VERIFICATION OF TRANSLATION

Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned attorney respectfully submits in the above-captioned application the Verification of Translation for French Patent Application No. 97 07334 filed in the name of Biopharmex Holding SA.

Respectfully submitted,

John A. Evans, Reg. No. 44,100
Customer Number 30678
Connolly Bove Lodge & Hutz LLP
1990 M Street, N.W.
Washington, D.C. 20036-3425
Telephone: 202-331-7111

Date: February 1, 2002



RECEIVED
FEB - 8 2002
TC 3753 MAIL ROOM

IN THE MATTER OF FRENCH PATENT
APPLICATION N° 97 07334 FILED ON
IN THE NAME OF BIOPHARMEX HOLDING SA

VERIFICATION OF TRANSLATION

I, Laurence VERCAEMER, CABINET PLASSERAUD, 84 rue d'Amsterdam,
75440 PARIS CEDEX 09 hereby certify that the following is a true translation
to the best of my knowledge and belief of the priority document.

Signature

Paris, January 11, 2002

7

NIIP

NATIONAL
INSTITUTE OF
INDUSTRIAL
PROPERTY



RECEIVED
FEB-8 2002
TC 3703 MAIL ROOM

PATENT

**UTILITY CERTIFICATE – CERTIFICATE OF
ADDITION**

OFFICIAL COPY

The Director of the National Institute of Industrial
Property certifies that the attached document is
a true copy of an application for industrial property
titleright filed at the Institute.

Drawn up in Paris, October 27, 1997

On behalf of the Director of the National
Institute of Industrial Property
The Divisional Head

(signature)

Martine PLANCHE

NATIONAL
INSTITUTE OF
INDUSTRIAL
PROPERTY

REGISTERED OFFICE
16 bis, rue de Saint Petersburg
75800 PARIS CEDEX 08
Telephone : 01 53 04 53 04
Telefax : 01 42 94 86 54
<http://www.inpi.fr>

NIIP

NATIONAL INSTITUTE OF INDUSTRIAL PROPERTY

26 bis, rue de Saint Pétersbourg

75800 Paris Cedex 08

Telephone : 01 53 04 53 04

Telefax : 01 42 94 86 54

**PATE**

Cerfa

N° 11354*01

UTILITY CERTIFICATE

Intellectual Property Code - Book VI

REQUEST FOR GRANT 1 / 2

This form is to be completed in black ink and to be legible DB540W /190600

RESERVED FOR THE NIIP

SUBMISSION OF THE DOCUMENTS	June 13, 1997
DATE	
PLACE	
NATIONAL REGISTRATION N°	97 07334
ALLOTTED BY THE NIPI	
FILING DATE ALLOTTED BY THE NIIP	June 13, 97

1 NAME AND ADDRESS OF THE APPLICANT OR THE REPRESENTATIVE TO WHOM THE CORRESPONDANCE IS TO BE ADDRESSED

Maître Marie-José LEFEBVRE
Avocat à la Cour
104 av. Victor Hugo 75016 PARIS

RECEIVED
 FEB 8 2002
 370041 ROOM

Your references for this file :
 (optional)

Confirmation of filing by telefax	<input type="checkbox"/> N° Allotted by the NIIP
2 NATURE OF THE INDUSTRIAL PROPERTY RIGHT	Check the appropriate box below
Patent application	<input checked="" type="checkbox"/>
Utility Certificate application	<input type="checkbox"/>
Divisional application	<input type="checkbox"/>
Initial patent application	N° _____ Date _____
or Initial certificate of utility application	N° _____ Date _____
Conversion of a European patent Application	<input type="checkbox"/>
Initial patent application	N° _____ Date _____

3 TITLE OF THE INVENTION (maximum 200 characters)

Injectable implant for subcutaneous or intradermal injection, with a controlled resorbability, for reparative or plastic surgery and esthetic dermatology

4 PRIORITY DECLARATION OR APPLICATION FOR THE BENEFIT OF THE FILING DATE OF A PRIOR FRENCH APPLICATION

Country or organisation _____
 Date ____/____/____ N° _____
 Country or organisation _____
 Date ____/____/____ N° _____
 Country or organisation _____
 Date ____/____/____ N° _____
☐ If there are additional priorities, check the box and use the additional form « suite »

5 APPLICANT

☐ If there are additional applicants, check the box and use the additional form « Suite »

Name or Company name	BIOPHARMEX HOLDING SA	
First name(s)		
Legal form	SA	
SIREN N°	RC Luxembourg B59.280	
APE-NAF Code		
Address	Street	11 Boulevard Royal
	Postal code and City	L-2449 LUXEMBOURG
Country	Luxembourg	
Nationality	Luxembourg	
Telephone N° (optional)		
Telefax N° (optional)		
Electronic Address (optional)		

D


UTILITY CERTIFICATE

REQUEST FOR GRANT 2/2

RESERVED FOR THE NIIP

SUBMISSION OF DOCUMENTS:			
DATE			
PLACE			
NATIONAL REGISTRATION N° ALLOTTED BY THE NIIP		97 07334	
		DB 540 W /190600	
Your references for this file <i>(optional)</i>			
6 REPRESENTATIVE			
Name		LEFEBVRE	
First name		Marie-José	
Company name		Avocat à la Cour	
N° of permanent power of Attorney			
Address	Street	104 avenue Victor Hugo	
	Postal code and City	75016	PARIS
Telephone No. <i>(optional)</i>			
Telefax No. <i>(optional)</i>			
Electronic address <i>(optional)</i>			
7 INVENTOR (S)			
The Inventors are the applicants		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No In this case provide a separate designation of inventor(s)	
8 SEARCH REPORT		Only for a patent application (including division and transformation)	
Request for immediate examination		<input checked="" type="checkbox"/>	
Or deferred examination		<input type="checkbox"/>	
Payment at intervals of the fee		Payment in two stages, only for individuals	
		<input type="checkbox"/> Yes	
		<input type="checkbox"/> No	
9 REDUCTION OF FEES		Only for individuals	
		<input type="checkbox"/> Requested for the first time <i>(Attach copy of the income-tax form)</i> <input type="checkbox"/> Requested prior to filing <i>(Attach copy of the favourable decision or indicate its reference) :</i>	
If the additional form « Suite » has been used, indicate the number of pages annexed			
10 SIGNATURE OF THE APPLICANT OR REPRESENTATIVE (Name and capacity of the signatory)		OFFICIAL STAMP	

PATENT DEPARTMENT
26 bis, rue de Saint Pétersbourg
75800 Paris Cedex 08
Telephone : 01 53 04 53 04



Telefax : 01 42 94 86 54

UTILITY CERTIFICATE

Intellectual Property Code – Book VI

DESIGNATION OF INVENTOR(S) Page No. 1/2
(if the Applicant is not the Inventor or the sole Inventor)

This document is to be completed in black ink and to be legible DB 113 W
/260899

Your references for this file (optional)			
NATIONAL REGISTRATION N°		97 07334	
TITLE OF THE INVENTION (maximum 200 characters)			
Injectable implant for subcutaneous or intradermal injection, with a controlled resorbability, for reparative or plastic surgery and esthetic dermatology			
APPLICANT(s)			
BIOPHARMEX HOLDING SA 11 Boulevard Royal L-2449 Luxembourg			
DESIGNATE(S) AS INVENTOR(S) : (If there are more than 3 inventors, use an additional identical form and number each page, indicating the total number of pages)			
Name		ASIUS	
First name(s)		Jérôme	
Address	Street	23 rue de l'Aiguillerie	
	Postal code and City	34000	Montpellier
Company name (optional)			
Name		FESSI	
First name(s)		Hatem	
Address	Street	40 rue d'Aubigny	
	Postal code and City	69003	Lyon
Company name (optional)			
Name		GOUCHET	
First name(s)		Franck	
Address	Street	8 allée des Chasseurs	
	Postal code and City	45450	Donnery
Company name (optional)			
10 SIGNATURE OF THE APPLICANT OR REPRESENTATIVE (Name and capacity of the signatory)			

The Law n° 78/17 of January 6, 1978 concerning computers, files and freedoms applies to the responses made on this form. This Law guarantees a right of access and of rectification of data before the NIIP

D

PATENT DEPARTMENT
26 bis, rue de Saint Pétersbourg
75800 Paris Cedex 08
Telephone : 01 53 04 53 04

Telefax : 01 42 94 86 54

UTILITY CERTIFICATE

Intellectual Property Code – Book VI

DESIGNATION OF INVENTOR(S) Page No. 21..2
(if the Applicant is not the Inventor or the sole Inventor)

This document is to be completed in black ink and to be legible DB 113 W
/260899

Your references for this file (optional)			
NATIONAL REGISTRATION N°		97 07334	
TITLE OF THE INVENTION (maximum 200 characters)			
Injectable implant for subcutaneous or intradermal injection, with a controlled resorbability, for reparative or plastic surgery and esthetic dermatology			
APPLICANT(s)			
BIOPHARMEX HOLDING SA 11 Boulevard Royal L-2449 Luxembourg			
DESIGNATE(S) AS INVENTOR(S) : (If there are more than 3 inventors, use an additional identical form and number each page, indicating the total number of pages)			
Name		LAGLENNE	
First name(s)		Bénédicte	
Address	Street	23 rue de l'Aiguillerie	
	Postal code and City	34000	Montpellier
Company name (optional)			
Name		LAUGIER-LAGLENNE	
First name(s)		Elisabeth	
Address	Street	25-27 rue Tronchet	
	Postal code and City	75008	Paris
Company name (optional)			
Name			
First name(s)			
Address	Street		
	Postal code and City		
Company name (optional)			
10 SIGNATURE OF THE APPLICANT OR REPRESENTATIVE (Name and capacity of the signatory)			

The Law n° 78/17 of January 6, 1978 concerning computers, files and freedoms applies to the responses made on this form. This Law guarantees a right of access and of rectification of data before the NIIP

D



DOCUMENT COMPRISING AMENDMENTS

5	Page(s) of the description or claims or drawing sheet			R.M.*	Date of letter	Date stamp of examiner
	Amended	Deleted	Added			
	1, 3, 4, 5	-	-	RM	Aug. 14, 97	Sept. 8, 97 / J.A.B.

10

An amendment in the original claims, unless resulting from the disposition of article 28 of the Décret of Sept. 19, 1979, is signaled by the mention "RM" (Revendications Modifiées = amended claims).

5



DOCUMENT COMPRISING AMENDMENTS

5	Page(s) of the description or claims or drawing sheet	R.M.*	Date of letter	Date stamp of examiner
	<u>Amended</u> <u>Deleted</u> <u>Added</u>			
	1, 3, 4, 5 - -	RM	Aug. 14, 97	Sept. 8, 97 / J.A.B.

10

An amendment in the original claims, unless resulting from the disposition of article 28 of the Decret of Sept. 19, 1979, is signaled by the mention "RM" (Revendications Modifiées = amended claims).

D



The present invention relates to an implant for subcutaneous or intradermal injection, resorbable in a given time, intended to be used in reparative or plastic surgery and in esthetic dermatology, for filling wrinkles, fine lines, skin cracks, acne scars and other scars. The characteristics of the product are the ease of use without prior manipulations, the syringeability of the product, the efficacy of the microspheres which favor fibrosis, the resorbability in a controlled period of time of the microspheres as well as of the vector gel, the absence of allergenicity of the product, which makes any prior test unnecessary.

Up until now, a number of products have been used. Each product has advantages and disadvantages :

• Silicone gel (or silicone oil) is easy to use. However, the migration of droplets of silicone into the tissues situated below the point of injection, by simple gravity, has been observed after injection. Silicone is frequently the cause of chronic inflammation, of formation of granulomas, and even of tardive allergic reactions. Silicone is not biodegradable, and it is often found in the liver.

• Teflon paste is a suspension of polytetrafluoroethylene particles (diameter 10 to 100 μm) in glycerine. This product, in numerous cases, caused severe and chronic serious infections and had to be removed after a few months from dermal and subdermal tissues for most patients. It has also been proved that small polytetrafluoroethylene particles were found in the liver.

• Collagen suspensions have been very widely used in the last ten years. The results have however been quite disappointing since collagen is resorbed within 1 to 3 months. Allergic reactions are also noted in about 2% of patients . Finally, it should be noted that collagen is of bovine origin.

• Biological samples from the patient herself/himself: the idea was certainly interesting, but clinical experience has shown the failure of the reimplantation of the fatty cells, which are absorbed and disappear within a few weeks.

Another system consisted in adding plasma from the patient to a collagen gelatin of bovine and porcine origins. The results are even more disappointing, and the product is of animal origin.

• Hyaluronate gels provided a good alternative by virtue of their biocompatibility and their lack of toxicity. They are moreover widely used in eye surgery. However, their rapid bioresorbability (maximum 2 months) makes them ineffective for use in plastic surgery.

• Bioplastics are polymerized silicone particles (diameter 70 to 140 μ) dispersed in polyvinylpyrrolidone. The product had to be withdrawn given the chronic inflammation and the rejection reactions caused by it.

- Polymethylmethacrylate (PMMA) microspheres having a diameter of 20 to 40 μ in suspension either in a solution of gelatin or in a solution of collagen. PMMA is not biodegradable, but not enough time has elapsed in order to know what this implant gives after 5 or 6 years. Moreover, the vector remains a solution of collagen of bovine origin, with the problems of allergy which are known for it.

The product of the invention is an implant :

- resorbable in a controlled manner. The idea is first to have an implant which is resorbable after 1 year, to allow for possible esthetics corrections. Secondly, the implant will only be resorbed after 3 years. In no case does a non-resorbable implant appear to be desirable. It is still a foreign body placed in a live tissue.

- based on the principle of microspheres in suspension in a gel. These microspheres should have a diameter higher than 5 μ , and preferably higher than 20 μ , so as not be absorbed by macrophages. They should have a diameter lower than 150 μ , and preferably lower than 40 μ , so as on the one hand to be injectable by a fine needle and on the other hand not to create granular masses under the finger.

- these microspheres are constituted of a neutral polymer chosen for its innocuousness and already largely used by the pharmaceutical industry either orally or parenterally.

The microspheres should have a controlled bioresorbability, to be adapted to the two types of product described here above, either in a first aim with a resorbability period of up to 1 year or, in a second aim, with a resorbability period of 1 to 3 years. This means that the polymer will degrade itself in situ into compounds of low molecular weight which will be eliminated from the organism by natural processes.

Two families of polymers essentially meet the preceding definition : the polycaprolactones (and in particular the poly- ϵ -caprolactones), the lactides (polylactic acids or PLA) and glycosides (polyglycolic acids or PLAGA).

Given the numerous studies already carried out and the good knowledge of the products, in particular as regards the manufacture of microspheres and resorbability, it appears advantageous to use a mixture of polylactic acid (PLA) and polylactic-co-glycolic acid (PLAGA). The proportions of each of these two acids make it possible to determine the remanence of the product.

Bioresorbable synthetic polymers have been studied for about 15 years under the direction of Michel VERT, Director of Research at C.N.R.S. The first clinical uses of PLAs started in 1981 for various indications in facial traumatology. The use of lactic acid polymers has become systematic in the context of bioresorbable surgical implants. PLAs now have

diverse and wide medical applications (bone surgery, maxillo-facial surgery, controlled-release pharmacological formulations: implants, microspheres, nanospheres, vaccines).

5 The degradation of lactic acid polymers in biological medium occurs exclusively by a chemical mechanism of nonspecific hydrolysis. The products of this hydrolysis are then metabolized and then eliminated by the human body. Chemical hydrolysis of the polymer is complete; the more pronounced its amorphous character and the lower its molecular mass, the more rapidly it occurs. The biocompatibility of the PLA and PLAGA polymers makes them excellent supports for cellular growth and tissue regeneration.

10 The microspheres are included in a gel. This gel, which is used as vector to maintain the microspheres in a homogeneous suspension, is resorbable within approximately 2 months, which corresponds to the time necessary for the creation of fibroses around the microspheres. It consists mainly of water for injection and a gelling agent authorized in injection: cellulose derivatives, and more particularly carboxymethylcellulose (CMC) at a concentration of 0.1 to 7.5%, and preferably from 0.1 to 5.0%. It is also possible to use hydroxypropylmethylcellulose (HPMC) which is commonly used in intra-ocular injection in the context of cataract operations. 15 It is also possible to use a synthetic hyaluronic acid, which is used for intra-ocular injections and subcutaneous injections. It is also possible to use lactic acid esters, caproic acid esters and the like.

20 The good dispersion of the microspheres and the homogeneity of the gel will be provided by the use of a surfactant chosen for its innocuousness and its authorized subcutaneous and intradermal use. Tween 80 or pluronic acid can be used.

- The product is provided in ready-for-use prefilled sterile syringes, provided with a needle, or in vials of sterile suspension.
- The implant does not require a test of allergenicity. It does not contain any product 25 of animal origin.

The protocol for the manufacture of the implant is described below :

- Preparation of microspheres of lactic acid polymer. The conventional solvent evaporation technique, or the so-called controlled precipitation technique or any other technique which makes it possible to obtain microspheres of the desired size is used.
- 30 • Preparation of a gel of sufficient viscosity to maintain the microspheres in suspension. This viscosity will be adjusted depending on the size of the microspheres and the proportion of microspheres dispersed in the gel. This proportion will be from 5 to 30 % (weight/volume) preferably from 10 to 20 %.
- Distribution of the gel into syringes or into vials, in a controlled atmosphere (class 35 10⁴).

- Sterilization of the vials or syringes, or use of a process which makes the finished product suitable for injection by the subcutaneous route.

Examples of finished products according to the invention :

5

EXAMPLE A

2 g of PLA are dissolved in 20 ml of an organic solvent (ethylacetate). This solution is dispersed in 100 ml of water containing 5 g of surfactant (Tween 80). Moderate vortex stirring is maintained until evaporation of the solvent and formation of microspheres having a mean diameter of 40 μ . The microspheres formed are recovered by sedimentation, filtration and drying. They are then included in a gel consisting of water and CMC (0.5%) . After moderate stirring, the distribution is carried out.

EXAMPLE B

2 g of PLA are dissolved in 20 ml of an organic solvent (methylene chloride). This solution is dispersed in 100 ml of water containing 5 g of surfactant (Tween 80). Moderate vortex stirring is maintained until evaporation of the solvent and formation of microspheres having a mean diameter of 80 μ . The microspheres formed are recovered by sedimentation, filtration and drying. They are then included in a gel consisting of water and CMC (0.5%). After moderate stirring, the distribution is carried out.

EXAMPLE C

20

2 g of PLA are dissolved in 20 ml of an organic solvent (chloroform). This solution is dispersed in 100 ml of water containing 5 g of surfactant (Tween 80). Moderate vortex stirring is maintained until evaporation of the solvent and formation of microspheres having a mean diameter of 50 μ . The microspheres formed are recovered by sedimentation, filtration and drying. They are then included in a gel consisting of water and HPMC (1%). After moderate stirring, the distribution is carried out.

25

Claims

1. Injectable implants consisting of bioresorbable microspheres in suspension in a gel.
2. Implants according to Claim 1, characterized in that the microspheres consist of
5 poly- ϵ -caprolactone, lactic acid polymers, lactic co-glycolic acid polymers, lactides, glycosides, or a mixture thereof.
3. Implants according to Claim 1, characterized in that the proportion of microspheres in the gel is from 5 to 30 %, preferably from 10 to 20 %.
4. Implants according to Claim 1, characterized in that the microspheres have a mean
10 diameter of from 5 to 150 μ , and preferably from 20 to 40 μ .
5. Implants according to Claim 1, characterized in that the microspheres are bioresorbable within a period of 6 months to 3 years.
6. Implants according to Claim 1, characterized in that the gel medium includes
15 mainly, as gelling agent, carboxymethylcellulose (CMC) at a concentration of 0.1 to 7.5%, and preferably from 0.1 to 5.0%.

The present invention relates to an implant for subcutaneous injection, resorbable in a given time, intended to be used in reparative or plastic surgery and in esthetic dermatology, for filling wrinkles, fine lines, skin cracks, acne scars and other scars. The characteristics of the product are the ease of use without prior manipulations, the syringeability of the product, the efficacy of the microspheres which favors fibrosis, the resorbability in a controlled period of time of the microspheres as well as of the vector gel, the absence of allergenicity of the product, which makes any prior test unnecessary.

Up until now, a number of products have been used. Each product has advantages and disadvantages :

• Silicone gel (or silicone oil) is easy to use. However, the migration of droplets of silicone into the tissues situated below the point of injection, by simple gravity, has been observed after injection. Silicone is frequently the cause of chronic inflammation, of formation of granulomas, and even of tardive allergic reactions. Silicone is not biodegradable, and it is often found in the liver.

• Suspension of polytetrafluoroethylene particles (diameter 10 to 100 μm) in glycerine. This product, in numerous cases, caused severe and chronic serious infections and had to be removed after a few months from dermal and subdermal tissues for most patients. It has also been proved that small polytetrafluoroethylene particles were found in the liver.

• Collagen suspensions have been very widely used in the last ten years. The results have however been quite disappointing since collagen is resorbed within 1 to 3 months. Allergic reactions are also noted in about 2% of patients . Finally, it should be noted that collagen is of bovine origin.

• Biological samples from the patient herself/himself: the idea was certainly interesting, but clinical experience has shown the failure of the reimplantation of the fatty cells, which are absorbed and disappear within a few weeks.

Another system consisted in adding plasma from the patient to a collagen gelatin of bovine and porcine origins. The results are even more disappointing, and the product is of animal origin.

• Hyaluronate gels provided a good alternative by virtue of their biocompatibility and their lack of toxicity. They are moreover widely used in eye surgery. However, their rapid bioresorbability (maximum 2 months) makes them ineffective for use in plastic surgery.

• Bioplastics are polymerized silicone particles (diameter 70 to 140 μ) dispersed in polyvinylpyrrolidone. The product had to be withdrawn given the chronic inflammation and the rejection reactions caused by it.

- Polymethylmethacrylate (PMMA) microspheres having a diameter of 20 to 40 μ in suspension either in a solution of gelatin or in a solution of collagen. PMMA is not biodegradable, but not enough time has elapsed in order to know what this implant gives after 5 or 6 years. Moreover, the vector remains a solution of collagen of bovine origin, with the problems of allergy which are known for it.

The product of the invention is an implant :

- resorbable in a controlled manner. The idea is first to have an implant which is resorbable after 1 year, to allow for possible esthetics corrections. Secondly, the implant will only be resorbed after 3 years. In no case does a non-resorbable implant appear to be desirable.
- It is still a foreign body placed in a live tissue.

- based on the principle of microspheres in suspension in a gel. These microspheres should have a diameter higher than 5 μ , and preferably higher than 20 μ , so as not be absorbed by macrophages. They should have a diameter lower than 150 μ , and preferably lower than 40 μ , so as on the one hand to be injectable by a fine needle and on the other hand not to create granular masses under the finger.

- these microspheres are constituted of a neutral polymer chosen for its innocuousness and already largely used by the pharmaceutical industry either orally or parenterally.

The microspheres should have a controlled bioresorbability, to be adapted to the two types of product described here above, either in a first aim with a resorbability period of up to 1 year or, in a second aim, with a resorbability period of 1 to 3 years. This means that the polymer will degrade itself in situ into compounds of low molecular weight which will be eliminated from the organism by natural processes.

Two families of polymers essentially meet the preceding definition : the polycaprolactones (and in particular the poly- ϵ -caprolactones), the lactides (polylactic acids or PLA) and glycosides (polyglycolic acids or PLAGA).

Given the numerous studies already carried out and the good knowledge of the products, in particular as regards the manufacture of microspheres and resorbability, it appears advantageous to use a mixture of polylactic acid (PLA) and polylactic-co-glycolic acid (PLAGA). The proportions of each of these two acids make it possible to determine the remanence of the product.

Bioresorbable synthetic polymers have been studied for about 15 years under the direction of Michel VERT, Director of Research at C.N.R.S. The first clinical uses of PLAs started in 1981 for various indications in facial traumatology. The use of lactic acid polymers has become systematic in the context of bioresorbable surgical implants. PLAs now have

diverse and wide medical applications (bone surgery, maxillo-facial surgery, controlled-release pharmacological formulations: implants, microspheres, nanospheres, vaccines).

The degradation of lactic acid polymers in biological medium occurs exclusively by a chemical mechanism of nonspecific hydrolysis. The products of this hydrolysis are then metabolized and then eliminated by the human body. Chemical hydrolysis of the polymer is complete; the more pronounced its amorphous character and the lower its molecular mass, the more rapidly it occurs. The biocompatibility of the PLA and PLAGA polymers makes them excellent supports for cellular growth and tissue regeneration.

The microspheres are included in a gel. This gel, which is used as vector to maintain the microspheres in a homogeneous suspension, is resorbable within approximately 2 months, which corresponds to the time necessary for the creation of fibroses around the microspheres. It consists mainly of water for injection and a gelling agent authorized in injection: cellulose derivatives, and more particularly carboxymethylcellulose (CMC) at a concentration of 0.1 to 7.5%, and preferably from 0.1 to 5.0%. It is also possible to use hydroxypropylmethylcellulose (HPMC) which is commonly used in intra-ocular injection in the context of cataract operations. It is also possible to use a synthetic hyaluronic acid, which is used for intra-ocular injections and subcutaneous injections. It is also possible to use lactic acid esters, caproic acid esters and the like.

The good dispersion of the microspheres and the homogeneity of the gel will be provided by the use of a surfactant chosen for its innocuousness and its authorized subcutaneous and intradermal use: Polyoxyethylene sorbitan monooleate or pluronic acid can be used.

- The product is provided in ready-for-use prefilled sterile syringes, provided with a needle, or in vials of sterile suspension.
- The implant does not require a test of allergenicity. It does not contain any product of animal origin.

The protocol for the manufacture of the implant is described below :

- Preparation of microspheres of lactic acid polymer. The conventional solvent evaporation technique, or the so-called controlled precipitation technique or any other technique which makes it possible to obtain microspheres of the desired size is used.
- Preparation of a gel of sufficient viscosity to maintain the microspheres in suspension. This viscosity will be adjusted depending on the size of the microspheres and the proportion of microspheres dispersed in the gel. This proportion will be from 5 to 30 % (weight/volume) preferably from 10 to 20 %.
- Distribution of the gel into syringes or into vials, in a controlled atmosphere (class 10⁴).

Claims

1. Injectable implants consisting of bioresorbable microspheres in suspension in a gel.
2. Implants according to Claim 1, characterized in that the microspheres consist of
5 poly- ϵ -caprolactone, lactic acid polymers, lactic co-glycolic acid polymers, lactides, glycosides, or a mixture thereof.
3. Implants according to Claim 1, characterized in that the proportion of microspheres in the gel is from 5 to 30 %, preferably from 10 to 20 %.
4. Implants according to Claim 1, characterized in that the microspheres have a mean
10 diameter of from 5 to 150 μ , and preferably from 20 to 40 μ .
5. Implants according to Claim 1, characterized in that the microspheres are bioresorbable within a period of 1 year to 3 years.
6. Implants according to Claim 1, characterized in that the gel medium includes
15 mainly, as gelling agent, carboxymethylcellulose (CMC) at a concentration of 0.1 to 7.5%, and preferably from 0.1 to 5.0%.

D